Select Page

Lead article on FDA regulation of ophthalmic drugs

Dr. Novack published the lead article in the June 2024 issue of the American Journal of Ophthalmology. In this article, he showed a time line of key U.S. FDA registration and the availability of ocular hypotensive drugs (i.e., drugs that decrease elevated intraocular pressure) to patients and their doctors. He concludes that “Concomitant with public health events, the laws that the US Congress enacted in response to these events, as well as increasing scientific standards have been increased magnitude and quality of the
clinical data used to support the these now sterile, stable, safe, and effective drug products into our therapeutic pharmacopeia, while providing rapid review of NDAs.

AJO cover June 2024
Recent Posts

Gary D. Novack, PhD, president of PharmaLogic Development

Dr. Novack speaking at ASCRS 2014

Dr. Novack talked in two symposia at the Glaucoma 360 event of the Glaucoma Research Foundation in San Francisco.

PharmaLogic sponsor a northern California bicycle riding team “Caballo Rojo

UCSC Chancellor George Blumenthal and Foundation President Ken Doctor thank Dr. Novack for his service to UCSC.

Dr. Novack on floor of California State Assembly with Assemblymember Beall (D-San Jose)

Dr. Novack addresses European Glaucoma Society on Generic Drugs

Dr. Novack with Dr. Wiley Chambers (FDA/CDER), Dr. Ellen Strahlman (CMO GSK), and Dr. Malvina Eydelman (FDA/CDRH) at the Glaucoma 360 event.

Dr. Novack speaking at International Symposium on Ocular Pharmacology and Therapeutics, Vienna, Austria

Dr. Elizabeth Moyer and Dr. Novack at ophthalmology workshop European Medicines Agency

Dr. Novack presents young investigator award at ASPET to Stephanie Piecewicz of MIT